State Street® SPDR® S&P® Pharmaceuticals ETF

State Street® SPDR® S&P® Pharmaceuticals ETF

About

State Street® SPDR® S&P® Pharmaceuticals ETF (US78464A7220) is a US-listed physically replicated equity ETF tracking the S&P Pharmaceuticals Select Industry Index. With a expense ratio of 0.35%, it is moderately priced, paying distributions. The fund holds 66 positions across 1 region with 464M in assets, with heavy concentration — 79% in United States, 79% in Health Care, launched in 2006. Over the past year, the fund returned 44.6%. We rate this fund 5.7/10.

5.7
  • 21%Tracking Difference10.0
  • TD Consistency
  • 9%Expense Ratio3.3
  • 11.25%Holding Count3.5
  • 22.5%Country Concentration4.8
  • 11.25%Sector Concentration1.0
  • 25%Assets Under Management6.8

Scores are scaled 1–10 on a logarithmic curve relative to all ETFs in the database. Data sources: provider factsheets, exchange data, and NAV history. Information for educational purposes only — not investment advice. Last updated: Jul 14, 2026

Ticker XPH
ISIN
Fund Size $463.9M
Issuer SPDR
Distribution Pays Distributions
Replication Physical
Inception Jun 2006
Base Currency USD
Index S&P Pharmaceuticals Select Industry Index
Asset Class Equities
Category Equity Sector

Costs

8.0
This fund has low total costs, with competitive tracking and expense ratios.

Cost Metrics Explained

What expense ratio, tracking difference, and TD consistency measure

Expense ratio (Total Expense Ratio) is the annual fee the fund charges, deducted from assets. It’s the headline cost, but not the full picture.

Tracking Difference measures how much the fund actually lags (or leads) its benchmark index per year. This is the single best measure of true cost — it captures the expense ratio plus all other drags like sampling error and tax withholding. A lower (or negative) value is better.

TD Consistency measures how stable the tracking difference is from year to year. A low value means predictable, reliable costs; a high value means costs can vary significantly.

Expense Ratio0.35%
 
Metric Value
Expense Ratio 0.35%

Cumulative Returns

Performance across different time periods.
1 Month+1.09%
3 Months+0.25%
Year to Date+4.11%
1 Year+44.61%
3 Years+15.34%
5 Years+4.24%
Inception+8.56%
 
Period Cumulative Return
1 Month +1.09%
3 Months +0.25%
6 Months +0.24%
1 Year +44.61%
3 Years +15.34%
5 Years +4.24%
10 Years +3.96%
YTD +4.11%
Since Inception +8.56%

Holdings

3.5
With only 66 individual holdings, this fund is relatively concentrated compared to other ETFs.
 
Holding Weight
DEFINIUM THERAPEUTICS INC 2.88%
MBX Biosciences Inc 2.81%
Alumis Inc 2.05%
Enliven Therapeutics Inc 2.04%
Trevi Therapeutics Inc 2.02%
Amylyx Pharmaceuticals Inc 2.01%
MAZE THERAPEUTICS INC 1.98%
VERADERMICS INC 1.98%
AtaiBeckley Inc 1.98%
Ligand Pharmaceuticals Inc 1.95%
Nektar Therapeutics 1.94%
Harrow Inc 1.89%
Crinetics Pharmaceuticals Inc 1.85%

Sectors

1.0
This fund is concentrated in just a few of its 2 sectors, reducing diversification.
 
Sector Weight
Health Care 78.59%
Unknown 21.41%

Regions

4.8
This fund is concentrated in just 2 countries, with significant geographic concentration.
 
Country Weight
United States 78.59%
UNKNOWN 21.41%

Nerd Stuff

Advanced risk and return metrics (17 July 2023 — 7 July 2026).
20.2%
Volatility
-24.0%
Max Drawdown
0.86
Sharpe Ratio
1.25
Sortino Ratio
0.72
Calmar Ratio
0.23
Beta
12.65%
Alpha (Jensen's)
0.033
Benchmark-relative metrics (Beta, Alpha, R²) are calculated against the iShares Core S&P 500 ETF (IE00B5BMR087).

Documents

Regulatory and fund documents.
Feedback
ETFs
Basket
Compare